Prostate cancer cell line experiments utilizing a previously validated OR51E1 agonist nonanoic acid and the structurally related non-agonist 1-nonanol [17, 18], induced cellular senescence and thus decreased tumor proliferation [19]. This evidence concerns the gene OR51E1 and prostate carcinoma.